Inhibition of the K
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
13 Dec 2023
13 Dec 2023
Historique:
received:
15
06
2023
accepted:
01
11
2023
medline:
14
12
2023
pubmed:
14
12
2023
entrez:
13
12
2023
Statut:
aheadofprint
Résumé
Existing antiarrhythmic drugs to treat atrial fibrillation (AF) have incomplete efficacy, contraindications and adverse effects, including proarrhythmia. AP30663, an inhibitor of the K
Identifiants
pubmed: 38092897
doi: 10.1038/s41591-023-02679-9
pii: 10.1038/s41591-023-02679-9
doi:
Banques de données
ClinicalTrials.gov
['NCT04571385']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Hindricks, G. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 42, 373–498 (2021).
doi: 10.1093/eurheartj/ehaa612
pubmed: 32860505
January, C. T. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130, e199–e267 (2014).
pubmed: 24682347
pmcid: 4676081
Pluymaekers, N. A. H. A. et al. Early or delayed cardioversion in recent-onset atrial fibrillation. N. Engl. J. Med. 380, 1499–1508 (2019).
doi: 10.1056/NEJMoa1900353
pubmed: 30883054
Shunmugam, S. R. et al. A double-blind, randomised, placebo-controlled, cross-over study assessing the use of XEN-D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy. J. Interv. Card. Electrophysiol. 51, 191–197 (2018).
doi: 10.1007/s10840-018-0318-2
pubmed: 29460236
Podd, S. J., Freemantle, N., Furniss, S. S. & Sulke, N. First clinical trial of specific IKACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation. Europace 18, 340–346 (2016).
doi: 10.1093/europace/euv263
pubmed: 26462707
Walfridsson, H. et al. Is the acetylcholine-regulated inwardly rectifying potassium current a viable antiarrhythmic target? Translational discrepancies of AZD2927 and A7071 in dogs and humans. Europace 17, 473–482 (2015).
doi: 10.1093/europace/euu192
pubmed: 25082948
Miyazawa, K. et al. Cross-ancestry genome-wide analysis of atrial fibrillation unveils disease biology and enables cardioembolic risk prediction. Nat. Genet. 55, 187–197 (2023).
doi: 10.1038/s41588-022-01284-9
pubmed: 36653681
pmcid: 9925380
Sollis, E. et al. The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource. Nucleic Acids Res. 51, D977–D985 (2023).
doi: 10.1093/nar/gkac1010
pubmed: 36350656
Heijman, J. et al. Enhanced Ca
doi: 10.1161/CIRCRESAHA.122.321858
pubmed: 36927079
Diness, J. G. et al. Inhibition of small-conductance Ca
doi: 10.1161/CIRCEP.110.957407
pubmed: 20562443
Qi, X.-Y. et al. Role of small-conductance calcium-activated potassium channels in atrial electrophysiology and fibrillation in the dog. Circulation 129, 430–440 (2014).
doi: 10.1161/CIRCULATIONAHA.113.003019
pubmed: 24190961
Haugaard, M. M. et al. Pharmacologic inhibition of small-conductance calcium-activated potassium (SK) channels by NS8593 reveals atrial antiarrhythmic potential in horses. Heart Rhythm 12, 825–835 (2015).
doi: 10.1016/j.hrthm.2014.12.028
pubmed: 25542425
Gatta, G. et al. Effective termination of atrial fibrillation by SK channel inhibition is associated with a sudden organization of fibrillatory conduction. Europace 23, 1847–1859 (2021).
doi: 10.1093/europace/euab125
pubmed: 34080619
pmcid: 8576281
Diness, J. G. et al. The K
doi: 10.3389/fphar.2020.00159
pubmed: 32180722
pmcid: 7059611
Bentzen, B. H. et al. Mechanisms of action of the K
doi: 10.3389/fphar.2020.00610
pubmed: 32477117
pmcid: 7232560
Gal, P. et al. First clinical study with AP30663—a K
doi: 10.1111/cts.12835
pubmed: 32725783
pmcid: 7719388
Fedida, D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin. Investig. Drugs 16, 519–532 (2007).
doi: 10.1517/13543784.16.4.519
pubmed: 17371199
Simó-Vicens, R., Sauter, D. R. P., Grunnet, M., Diness, J. G. & Bentzen, B. H. Effect of antiarrhythmic drugs on small conductance calcium-activated potassium channels. Eur. J. Pharmacol. 803, 118–123 (2017).
doi: 10.1016/j.ejphar.2017.03.039
pubmed: 28322838
Simon, A. et al. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department. Europace 19, 233–240 (2017).
pubmed: 28175295
Camm, A. J. et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J. Am. Coll. Cardiol. 57, 313–321 (2011).
doi: 10.1016/j.jacc.2010.07.046
pubmed: 21232669
McIntyre, W. F. et al. Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis. Europace 21, 1159–1166 (2019).
doi: 10.1093/europace/euz175
pubmed: 31292622
pmcid: 6680366
Diness, J. G. et al. Termination of vernakalant-resistant atrial fibrillation by inhibition of small-conductance Ca
doi: 10.1161/CIRCEP.117.005125
pubmed: 29018164
pmcid: 5647113
Tisdale, J. E. et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation 142, e214–e233. (2020).
doi: 10.1161/CIR.0000000000000905
pubmed: 32929996
Falk, R. H., Pollak, A., Singh, S. N. & Friedrich, T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J. Am. Coll. Cardiol. 29, 385–390 (1997).
doi: 10.1016/S0735-1097(96)00506-2
pubmed: 9014993
Reisinger, J. et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am. J. Cardiol. 81, 1450–1454 (1998).
doi: 10.1016/S0002-9149(98)00223-9
pubmed: 9645896
Torp-Pedersen, C. et al. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. Circ. Arrhythm. Electrophysiol. 4, 637–643 (2011).
doi: 10.1161/CIRCEP.111.962340
pubmed: 21841207
Stambler, B. S. et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 94, 1613–1621 (1996).
doi: 10.1161/01.CIR.94.7.1613
pubmed: 8840852
Pratt, C. M. et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am. J. Cardiol. 106, 1277–1283 (2010).
doi: 10.1016/j.amjcard.2010.06.054
pubmed: 21029824
Roy, D. et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 117, 1518–1525 (2008).
doi: 10.1161/CIRCULATIONAHA.107.723866
pubmed: 18332267
Roy, D. et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J. Am. Coll. Cardiol. 44, 2355–2361 (2004).
doi: 10.1016/j.jacc.2004.09.021
pubmed: 15607398